Probing T-cell response by sequence-based probabilistic modeling
With the increasing ability to use high-throughput next-generation sequencing to quantify the diversity of the human T cell receptor (TCR) repertoire, the ability to use TCR sequences to infer antigen-specificity could greatly aid potential diagnostics and therapeutics. Here, we use a machine-learni...
Saved in:
| Published in | PLoS computational biology Vol. 17; no. 9; p. e1009297 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
02.09.2021
PLOS Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1553-7358 1553-734X 1553-7358 |
| DOI | 10.1371/journal.pcbi.1009297 |
Cover
| Summary: | With the increasing ability to use high-throughput next-generation sequencing to quantify the diversity of the human T cell receptor (TCR) repertoire, the ability to use TCR sequences to infer antigen-specificity could greatly aid potential diagnostics and therapeutics. Here, we use a machine-learning approach known as Restricted Boltzmann Machine to develop a sequence-based inference approach to identify antigen-specific TCRs. Our approach combines probabilistic models of TCR sequences with clone abundance information to extract TCR sequence motifs central to an antigen-specific response. We use this model to identify patient personalized TCR motifs that respond to individual tumor and infectious disease antigens, and to accurately discriminate specific from non-specific responses. Furthermore, the hidden structure of the model results in an interpretable representation space where TCRs responding to the same antigen cluster, correctly discriminating the response of TCR to different viral epitopes. The model can be used to identify condition specific responding TCRs. We focus on the examples of TCRs reactive to candidate neoantigens and selected epitopes in experiments of stimulated TCR clone expansion. |
|---|---|
| Bibliography: | new_version ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 PMCID: PMC8476001 I have read the journal’s policy and the authors of this manuscript have the following competing interests: B.G. has received honoraria for speaking engagements from Merck, Bristol-Meyers Squibb, and Chugai Pharmaceuticals, has received research funding from Bristol-Meyers Squibb, and has been a compensated consultant for Darwin health, PMV Pharma and Rome Therapeutics of which he is a cofounder. |
| ISSN: | 1553-7358 1553-734X 1553-7358 |
| DOI: | 10.1371/journal.pcbi.1009297 |